TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19158152

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 669

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 669
Study: 16820267

Group type: EXPERIMENTAL
Intervention: Project EX-4 classroom-based intervention
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1097
Study: 15167707

Group type: EXPERIMENTAL
Intervention: Interferon-alpha2 (IFN-alpha2) treatment
Number of subjects: 22
Study: 11259325

Group type: EXPERIMENTAL
Intervention: Oral nateglinide (120 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous nateglinide (60 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both dosing routes
Number of subjects: 6
Study: 9874434

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted blood
Number of subjects: 221

Group type: COMPARATOR
Intervention: Packed red cells
Number of subjects: 221

Group type: COMPARATOR
Intervention: Untransfused patients
Number of subjects: 221
Study: 8067560

Group type: EXPERIMENTAL
Intervention: Monitored high-flow isoflurane
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Unmonitored high-flow isoflurane
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Monitored low-flow isoflurane
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Unmonitored low-flow isoflurane
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Monitored low-flow enflurane
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Unmonitored low-flow enflurane
Number of subjects: 253
Study: 2928063

Group type: EXPERIMENTAL
Intervention: Bizarre imagery in immediate cued-recall condition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bizarre imagery in delayed recall condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal imagery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mixed imagery
Number of subjects: 40
Study: 31654943

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter defibrillator (S‐ICD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transvenous implantable cardioverter defibrillator (TV‐ICD)
Number of subjects: 0
Study: 29042386

Group type: EXPERIMENTAL
Intervention: Healthy.me app for self-management of gout
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with modified Healthy.me app (only Gout Attack Diary)
Number of subjects: 0
Study: 26819445

Group type: EXPERIMENTAL
Intervention: P4P program
Number of subjects: 1458

Group type: COMPARATOR
Intervention: Non-P4P program
Number of subjects: 1458
Study: 24103632

Group type: EXPERIMENTAL
Intervention: VPA + Memantine (5 mg/day)
Number of subjects: 232

Group type: COMPARATOR
Intervention: VPA + Pbo
Number of subjects: 232
Study: 22364739

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 19562533

Group type: EXPERIMENTAL
Intervention: iv paracetamol 1 g preoperatively (Group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: iv paracetamol 1 g intraoperatively (Group II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline as placebo (Group III)
Number of subjects: 90
Study: 17659757

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC) treatment for 24 months
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Azathioprine with methylprednisolone (AZA) treatment for 24 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 87
Study: 16374010

Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery with CPB (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Coronary bypass surgery without CPB (OP, group B)
Number of subjects: 30
Study: 12205250

Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline
Number of subjects: 9374

Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline among those not obese at baseline
Number of subjects: 9374

Group type: COMPARATOR
Intervention: Baseline obesity
Number of subjects: 9374

Group type: EXPERIMENTAL
Intervention: Depressed mood at baseline among those obese at baseline
Number of subjects: 9374
Study: 9595977

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (6 MIU, 30 microg) administered via single intramuscular injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (6 MIU, 30 microg) administered in the placebo-controlled phase III clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a exposure to PLP-reactive murine T-cell lines
Number of subjects: 0
Study: 9761519

Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 38
Study: 1864026

Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride (alpha blocker)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prazosin hydrochloride
Number of subjects: 60
Study: 7056183

Group type: EXPERIMENTAL
Intervention: synthetic secretin
Number of subjects: 33

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 33
Study: 31833588

Group type: EXPERIMENTAL
Intervention: APPLE-Tree intervention (10-session group intervention with personalized goal-setting)
Number of subjects: 704

Group type: COMPARATOR
Intervention: Informational control group
Number of subjects: 704
Study: 31420050

Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment for 4 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment continued for another 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Open label placebo (OLP) treatment
Number of subjects: 100
Study: 26126810

Group type: EXPERIMENTAL
Intervention: BEC (S‐(2‐boronoethyl)‐L‐cysteine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAH group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BEC group
Number of subjects: 30
Study: 25624374

Group type: EXPERIMENTAL
Intervention: TAA‐AQ (110 μg once daily)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 23237936

Group type: EXPERIMENTAL
Intervention: Furosemide (0.3 mg/kg) combined with mannitol (1 g/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo combined with mannitol (1 g/kg)
Number of subjects: 23
Study: 21767149

Group type: EXPERIMENTAL
Intervention: Individualized Chinese herbal medicine (CHM) decoctions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo decoction (therapeutically inert)
Number of subjects: 40
Study: 19498098

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (70 maximal voluntary actions)
Number of subjects: 24
Study: 16687991

Group type: EXPERIMENTAL
Intervention: Escitalopram (mean dose 25.4+/‐6.6 mg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (during discontinuation phase)
Number of subjects: 13
Study: 15504188

Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg kg(‐1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Midazolam 0.30 mg kg(‐1)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 92
Study: 11785712

Group type: EXPERIMENTAL
Intervention: OAC (omeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: RAC (rabeprazole 20 mg bd, amoxycillin 750 mg bd and clarithromycin 400 mg bd for 1 week)
Number of subjects: 170
Study: 10092717

Group type: EXPERIMENTAL
Intervention: Magnesium hydroxide (MgOH) administration at a ratio of 5 mg of MgOH for every 1 mg of ingested elemental iron.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no MgOH administration).
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control).
Number of subjects: 16
Study: 7707164

Group type: EXPERIMENTAL
Intervention: Short-acting ACE inhibitors (captopril and quinapril) given twice a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting ACE inhibitors (enalapril, lisinopril, benazepril, cilazapril) given once a day
Number of subjects: 0
Study: 2666728

Group type: EXPERIMENTAL
Intervention: Kenalog
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gordox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyvinylpyrrolidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 904549

Group type: EXPERIMENTAL
Intervention: 0.15 g phenformin/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.15 g phenformin + 1.5 g clofibrate/day
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.5 g clofibrate/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31507034

Group type: EXPERIMENTAL
Intervention: Participatory Peer Research (PPR) intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 10
Study: 27745562

Group type: EXPERIMENTAL
Intervention: FuF labels with in‐aisle signs explaining the labels
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: FuF labels, no signage
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: MTL labels with in‐aisle signage
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: MTL labels, no signage
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group, no labels/signage
Number of subjects: 153
Study: 25963481

Group type: EXPERIMENTAL
Intervention: 20 mg pradigastat with a high-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg pradigastat with a low-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 40 mg pradigastat with a high-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pradigastat with a meal (pooled data from 13 studies)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasted or fed conditions (both 20 and 40 mg doses)
Number of subjects: 24
Study: 23571515

Group type: EXPERIMENTAL
Intervention: High-PEEP strategy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low-PEEP strategy
Number of subjects: 52
Study: 21640879

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with fixed appliances (bands and brackets)
Number of subjects: 24
Study: 20110014

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 37.5 mg tablets (study A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg tablets (study B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 225 mg tablet (study C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150 mg + 75 mg capsules (study D)
Number of subjects: 36
Study: 16304557

Group type: EXPERIMENTAL
Intervention: alfuzosin (10 or 15 mg) once daily for 3 months
Number of subjects: 536

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 536
Study: 15346071

Group type: EXPERIMENTAL
Intervention: Computer-assisted knee navigation system (Group N)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty without navigation (Group C)
Number of subjects: 64
Study: 11459681

Group type: EXPERIMENTAL
Intervention: Monopolar needles with large needle movement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Concentric needles with small needle movements (1 mm or less)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard insertion technique with large needle movement
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Needle handling technique with small needle movements
Number of subjects: 48
Study: 9292243

Group type: EXPERIMENTAL
Intervention: Finapres systolic pressure
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Finapres diastolic pressure
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beta‐adrenoceptor blockade with propranolol (160 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Beta‐adrenoceptor modulation with celiprolol (400 mg)
Number of subjects: 10
Study: 9244644

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 60
Study: 2576327

Group type: EXPERIMENTAL
Intervention: Theophylline and beta-adrenergic agonists combination
Number of subjects: 0
Study: 1119820

Group type: EXPERIMENTAL
Intervention: 1.0% colchicine in hydrophilic ointment applied once daily for 6 to 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% and 0.50% colchicine with occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrophilic petrolatum (thick viscous base)
Number of subjects: 0
Study: 31765315

Group type: EXPERIMENTAL
Intervention: Fast optic flow speed during RATW
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Slow optic flow speed during RATW in Hallway group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Optic flow speed manipulation (both slow and fast)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Immersive VR during RATW
Number of subjects: 28
Study: 31202270

Group type: EXPERIMENTAL
Intervention: Blended psychosocial support program based on Acceptance and Commitment Therapy
Number of subjects: 23
Study: 28431047

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 3280

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 3280

Group type: EXPERIMENTAL
Intervention: SYNTAX score II
Number of subjects: 3280
Study: 26314902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (2 hours prior to induction)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg (at night and 2 hours prior to induction)
Number of subjects: 100
Study: 23351633

Group type: EXPERIMENTAL
Intervention: 180 g of farmed Atlantic salmon, twice per week for 4 weeks
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 270 g of farmed Atlantic salmon, twice per week for 4 weeks
Number of subjects: 19
Study: 21481195

Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 16

Group type: COMPARATOR
Intervention: Human soluble insulin
Number of subjects: 16
Study: 19692689

Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 226

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 226
Study: 16467348

Group type: EXPERIMENTAL
Intervention: Oral protein energy supplements in addition to usual dietary advice
Number of subjects: 102

Group type: COMPARATOR
Intervention: Dietary advice alone
Number of subjects: 102
Study: 15259285

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (two tablets of an extract of aglycone isoflavones from red clover for 6 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11284785

Group type: EXPERIMENTAL
Intervention: 3 or 5 MU IFN‐alpha daily for 1 month, followed by the same dose three times a week for 11 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 MU IFN‐alpha three times a week for 1 year
Number of subjects: 38
Study: 9479781

Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10148709

Group type: EXPERIMENTAL
Intervention: Helmet advice from a physician
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Direct telephone communications
Number of subjects: 210

Group type: COMPARATOR
Intervention: No communication
Number of subjects: 210
Study: 3082301

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5% dextrose (D5W) solution plus electrolytes
Number of subjects: 35
Study: 30340468

Group type: EXPERIMENTAL
Intervention: DEMQOL (29 items)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: DEMQOL-proxy (32 items)
Number of subjects: 201
Study: 26986803

Group type: COMPARATOR
Intervention: Ongoing triple therapy (OT)
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted PI monotherapy (PI-mono)
Number of subjects: 587
Study: 24886378

Group type: EXPERIMENTAL
Intervention: Publication process management in the HALT‐C trial
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Tracking of manuscripts
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Data analyses
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Manuscript drafting
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Publications committee review and submission
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Overall publication timeline
Number of subjects: 1000
Study: 23297506

Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule (CXC) 2 capsules tid for 2 months
Number of subjects: 132

Group type: COMPARATOR
Intervention: Oral levofloxacin 0.2 g bid for 4‐6 weeks and oral Terazosin at 2 mg qd for 2 months
Number of subjects: 132
Study: 20439792

Group type: EXPERIMENTAL
Intervention: Prenatal and infancy home visiting by nurses
Number of subjects: 594
Study: 18611339

Group type: EXPERIMENTAL
Intervention: Modified regime with epinephrine (K=1 mg) and aminophylline (7 mg/kg)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Modified regime with epinephrine (K=2 mg) and aminophylline (7 mg/kg)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group with standard epinephrine treatment (1 mg every 3 minutes if no effect)
Number of subjects: 376
Study: 16271153

Group type: EXPERIMENTAL
Intervention: Amodiaquine hydrochloride chemoprophylaxis (CH+) every two weeks for seven months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No chemoprophylaxis (CH‐)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amodiaquine hydrochloride chemoprophylaxis (CH+)
Number of subjects: 0
Study: 12460329

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 10509763

Group type: EXPERIMENTAL
Intervention: Dietary olive oil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-oleic sunflower oil (HOSO)
Number of subjects: 24
Study: 7568792

Group type: EXPERIMENTAL
Intervention: Resovist at 4 mumol Fe/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resovist at 8 mumol Fe/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resovist at 16 mumol Fe/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resovist (all doses)
Number of subjects: 30
Study: 1952999

Group type: EXPERIMENTAL
Intervention: 30 U/m2/week growth hormone treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 15 U/m2/week growth hormone treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both doses of growth hormone treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 24
Study: 6396844

Group type: EXPERIMENTAL
Intervention: Chymopapain
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 60
Study: 30755256

Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (tTXA)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Intravenous Tranexamic Acid (ivTXA)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: tTXA
Number of subjects: 176

Group type: COMPARATOR
Intervention: ivTXA
Number of subjects: 176
Study: 27979361

Group type: EXPERIMENTAL
Intervention: Warm-up with MISTELS system exercises
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard practice (no warm-up)
Number of subjects: 16
Study: 27235823

Group type: EXPERIMENTAL
Intervention: Starter model food with high textural complexity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Starter model food with low textural complexity
Number of subjects: 0
Study: 25053129

Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with immunomodulating radiotherapy (8 Gy up to 12 Gy)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with preleukapheresis IFN-α (3 MU subcutaneous for 7 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate combined with both radiotherapy and preleukapheresis IFN-α
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vaccination with autologous DC loaded with tumor lysate/homogenate with neither radiotherapy nor preleukapheresis IFN-α
Number of subjects: 6
Study: 22520542

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 19719958

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 255
Study: 17355587

Group type: EXPERIMENTAL
Intervention: Intensive medication management (MedMgt)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (with or without medication)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Community care (CC)
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral treatment
Number of subjects: 579
Study: 14749863

Group type: EXPERIMENTAL
Intervention: 2.5% arginine hydrochloride ointment applied topically for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% arginine hydrochloride ointment
Number of subjects: 0
Study: 11176663

Group type: EXPERIMENTAL
Intervention: Minocycline, 200 mg/d for a median duration of 12 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg/d after minocycline withdrawal
Number of subjects: 12
Study: 9923586

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (various classes including diuretics, beta blocking agents, calcium channel blockers, ACE inhibitors, hypotensives)
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Beta blocking agents
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and diuretics
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Combination therapy (diuretic with beta blocking agent)
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Duration of hypertension
Number of subjects: 4294
Study: 7999291

Group type: EXPERIMENTAL
Intervention: Parodontax dentifrice
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 22
Study: 2784257

Group type: EXPERIMENTAL
Intervention: Interleukin-2 therapy
Number of subjects: 8
Study: 5505682

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32